Cytosorbents
Market Cap
US$353.6m
Last Updated
2020/11/26 23:12 UTC
Data Sources
Company Financials +
Executive Summary
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Cytosorbents's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CTSO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CTSO's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
-7.4%
CTSO
-1.5%
US Medical Equipment
2.1%
US Market
1 Year Return
107.9%
CTSO
16.3%
US Medical Equipment
19.8%
US Market
Return vs Industry: CTSO exceeded the US Medical Equipment industry which returned 16.3% over the past year.
Return vs Market: CTSO exceeded the US Market which returned 19.7% over the past year.
Shareholder returns
| CTSO | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.4% | -1.5% | 2.1% |
| 30 Day | -2.8% | -0.3% | 8.1% |
| 90 Day | -0.7% | 2.7% | 6.0% |
| 1 Year | 107.9%107.9% | 17.2%16.3% | 22.5%19.8% |
| 3 Year | 17.0%17.0% | 67.0%62.7% | 46.5%36.8% |
| 5 Year | 18.4%18.4% | 139.1%120.8% | 96.9%75.3% |
Long-Term Price Volatility Vs. Market
How volatile is Cytosorbents's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Analysts Are Updating Their Cytosorbents Corporation (NASDAQ:CTSO) Estimates After Its Third-Quarter Results1 month ago | Simply Wall St
Why Cytosorbents' (NASDAQ:CTSO) CEO Pay Matters2 months ago | Simply Wall St
When Can We Expect A Profit From Cytosorbents Corporation (NASDAQ:CTSO)?Valuation
Is Cytosorbents undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CTSO ($8.19) is trading below our estimate of fair value ($23.51)
Significantly Below Fair Value: CTSO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CTSO is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: CTSO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CTSO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CTSO's PB Ratio (4.4x) is in line with the US Medical Equipment industry average.
Next Steps
Future Growth
How is Cytosorbents forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
77.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CTSO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: CTSO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CTSO's is expected to become profitable in the next 3 years.
Revenue vs Market: CTSO's revenue (32.1% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: CTSO's revenue (32.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CTSO's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Cytosorbents performed over the past 5 years?
-13.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CTSO is currently unprofitable.
Growing Profit Margin: CTSO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CTSO is unprofitable, and losses have increased over the past 5 years at a rate of 13.3% per year.
Accelerating Growth: Unable to compare CTSO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTSO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.2%).
Return on Equity
High ROE: CTSO has a negative Return on Equity (-13.85%), as it is currently unprofitable.
Next Steps
Financial Health
How is Cytosorbents's financial position?
Financial Position Analysis
Short Term Liabilities: CTSO's short term assets ($96.8M) exceed its short term liabilities ($17.4M).
Long Term Liabilities: CTSO's short term assets ($96.8M) exceed its long term liabilities ($6.7M).
Debt to Equity History and Analysis
Debt Level: CTSO's debt to equity ratio (18.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CTSO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CTSO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CTSO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Cytosorbents's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CTSO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CTSO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTSO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTSO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTSO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.5yrs
Average management tenure
CEO
Phillip Chan (50 yo)
11.83yrs
Tenure
US$1,404,376
Compensation
Dr. Phillip P. Chan, M.D., Ph.D. has been the Chief Executive Officer of CytoSorbents Incorporated since January 2009 and served as its President until 2020. Dr. Chan serves as a Partner of NJTC Venture Fu...
CEO Compensation Analysis
Compensation vs Market: Phillip's total compensation ($USD1.40M) is about average for companies of similar size in the US market ($USD1.79M).
Compensation vs Earnings: Phillip's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 11.83yrs | US$1.40m | 0.97% $ 3.4m | |
| President & COO | 0.50yr | US$1.17m | 0.34% $ 1.2m | |
| CFO & Secretary | 7.5yrs | US$999.85k | 0.28% $ 985.2k | |
| Senior Vice President of Sales & Marketing | 8.42yrs | no data | no data | |
| Vice President of Business Development | 7.58yrs | no data | no data | |
| Chief Medical Officer | 0.50yr | no data | no data | |
| Co-Chairman of Cardiac Surgery Advisory Board & Consultant | 3.42yrs | US$97.32k | no data |
7.5yrs
Average Tenure
62yo
Average Age
Experienced Management: CTSO's management team is seasoned and experienced (7.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 11.83yrs | US$1.40m | 0.97% $ 3.4m | |
| Co-Chairman of Cardiac Surgery Advisory Board & Consultant | 3.42yrs | US$97.32k | no data | |
| Independent Chairman of the Board | 11.83yrs | US$311.00k | 0.13% $ 456.5k | |
| Independent Director | 6yrs | US$168.00k | 0% $ 0 | |
| Independent Director | 13.58yrs | US$156.95k | 0.022% $ 77.8k | |
| Member of Critical Care Advisory Board | no data | no data | no data | |
| Member of Critical Care Advisory Board | no data | no data | no data | |
| Chairman of the Trauma Advisory Board | no data | no data | no data | |
| Member of Trauma Advisory Board | no data | no data | no data | |
| Member of Trauma Advisory Board | no data | no data | no data | |
| Member of Trauma Advisory Board | 7.58yrs | no data | no data | |
| Chairman of Cardiac Surgery Advisory Board | 6.17yrs | no data | no data |
7.6yrs
Average Tenure
72yo
Average Age
Experienced Board: CTSO's board of directors are considered experienced (7.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.2%.
Top Shareholders
Company Information
Cytosorbents Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Cytosorbents Corporation
- Ticker: CTSO
- Exchange: NasdaqCM
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$353.609m
- Shares outstanding: 43.18m
- Website: https://www.cytosorbents.com
Number of Employees
Location
- Cytosorbents Corporation
- 7 Deer Park Drive
- Suite K
- Monmouth Junction
- New Jersey
- 8852
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CTSO | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jul 2006 |
| HQE1 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2006 |
Biography
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incor...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/11/26 23:12 |
| End of Day Share Price | 2020/11/25 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.